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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes 
death of motoneurons, resulting in paralysis, dysphagia, respiratory distress and 
ultimately death. The precise causes of this fatal disease are unknown, but the 
mechanisms contributing to motoneuron death have been researched extensively. 
Oxidative stress has been established as one mechanism of motoneuron death associated 
with ALS. Protein misfolding is a cellular dysfunction that occurs more commonly in 
increased levels of oxidative stress. Large concentrations of misfolded proteins interfere 
with neuron signaling and trigger apoptotic pathways leading to degeneration. Heat 
Shock Proteins (HSPs) are chaperones that assist in proper protein folding. The purpose 
of this research is to determine where and to what extent HSP levels are not being 
properly upregulated to counter the negative effects of oxidative stress associated with 
ALS, to determine their corresponding impact on cellular degeneration, and to assess the 
susceptibility of spinal motoneurons and muscle to oxidative stress. We perform a meta-
analysis of HSPs from 11 peer-reviewed experimental journal articles assessing HSP 
levels in the SOD1-G93A transgenic ALS mouse model.  Aggregated analysis of HSP 
levels in SOD1-G93A ALS transgenic mice revealed that HSPs are downregulated in the 
limbs at most stages of the disease, and are significantly lower than HSP levels in the 
spine. In contrast, HSP levels in the spine are significantly upregulated in comparison to 
wild type or non-ALS mice.  Since HSPs combat protein misfolding, the compensatory 
upregulation of HSPs in the ALS pathology is insufficient to counteract oxidative stress. 
Our results suggest that the muscle cells are more vulnerable to oxidative-related 
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degradation than spinal motoneurons.  In summary, HSPs as a clinical therapeutic 
strategy delivered to the muscle and/or spine could be particularly helpful in early stages 







Amyotrophic Lateral Sclerosis 
 Amyotrophic Lateral Sclerosis (ALS) is a deadly disease affecting an estimated 
450,000 people worldwide [2]. ALS is a neurodegenerative disease, targeting neurons of 
the spinal cord and brain stem. Those with ALS progressively lose control over their 
nervous system, initially inhibiting movement of appendages but ultimately resulting in 
the inability to use respiratory muscles [1]. The average survival of a newly diagnosed 
ALS patient is two to five years, with 20% of those diagnosed living longer than five 
years and only 10% living longer than 10 years after symptom onset [33]. About 90% of 
ALS cases are sporadic, meaning the disease occurs despite a lack of ALS history in the 
family. The other 10% of cases are familial, meaning the cause of the disease is 
genetically inherited [30]. While sporadic ALS occurs randomly and has no definitive 
causes, the etiology of familial ALS is more consistent. About 20% of familial ALS cases 
have been linked to a mutation in the copper/zinc Superoxide Dismutase (SOD1) gene. 
This discovery allowed for the genetic engineering of SOD1-mutated mice to be used for 
research purposes, and namely the SOD1 G93A (glycine 93 to alanine mutation) [4]. The 
SOD1 G93A transgenic mice replicate the corresponding clinical ALS phenotype, 
allowing researchers to discover potential causes or mechanisms of cell death.  
Nonetheless, the exact initiating causes of ALS remain largely unknown, although the 
resulting mechanisms of motoneuron death have been extensively experimentally 
examined. There is substantial experimental evidence from the SOD1 G93A transgenic 







 Oxidative stress is a result of an imbalance between the production of reactive 
oxygen species (ROS) in cells and the inability of the cell to remove ROS or repair the 
damage caused by excessive ROS levels. ROS are typically produced as byproducts of 
aerobic metabolism in the mitochondria. In large concentrations, ROS become highly 
toxic, triggering oxidative stress and resulting in negative effects like inflammation and 
protein misfolding. Typically, ROS are removed from cells, but mitochondria can “leak” 
ROS, resulting in an excess build-up of toxic ROS in the cell [4]. Pathological studies 
have shown that oxidative stress is increased in ALS, but it is unknown if oxidative stress 
is a result of the effects of ALS, or if it is the initiating cause of the disease. What is 
known is that, although motoneuron death in ALS is multifaceted and complex, oxidative 
stress has been established as one of the causes of motoneuron death [5]. 
 One method of cell death that is promoted by ROS toxicity related to oxidative 
stress is protein misfolding. Protein misfolding is a result of a dysfunctional change in 
three-dimensional folding, a physiological process that normally enables proteins to fold 
onto themselves. When proteins are not properly folded, they cannot perform their 
desired functions. Under  pathological conditions, misfolded proteins rapidly accumulate 
faster than they can be transported or destroyed.  The build-up of misfolded proteins 
interferes with neuronal communications, which triggers apoptotic pathways and the 
subsequent self-initiated killing of cells [34]. Cells have built-in mechanisms to combat the 
negative effects of physiological oxidative stress. The Heat Shock response is one of the 
primary mechanisms used to combat protein misfolding. 
 
Heat-Shock Proteins 
 HSPs are chaperones that assist in proper protein folding as well as the correction 
of misfolded proteins. It is known that under conditions of stress, properly functioning 
cells activate the Heat Shock response to synthesize neuroprotective HSPs. This 
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upregulation of HSPs provides the cell with protection against misfolded and damaged 
proteins, as the HSPs will chaperone the proteins to their normal, functioning structures 
[16]. HSP70, in particular, has been identified as a key HSP in correcting misfolded 
proteins and aiding in proper protein folding [38]. HSPs have been shown to play a major 
role in neurodegenerative diseases, and it has been suggested that activation of the Heat 
Shock response is indicative of vulnerability of cells to degeneration.  
 
Location of Initial ALS Degeneration 
There have been debates over whether neuronal degeneration in ALS begins at a more 
central location in the brain and spine (such as the soma of spinal motoneurons); within 
the long axons of the spinal motoneurons that extend from the spine to the target muscle 
cell; where the spinal motoneuron axon and muscle cell connect at the neuromuscular 
junctions (NMJ); or whether ALS begins in the muscle cells, themselves, with the disease 
retrogradely propagating across the NMJ, up the axon, and towards the spine [9]. Site-
specific examination of oxidative stress and the HSP response in the spinal motoneurons 
and in muscle can provide valuable information comparing the susceptibly of both sites’ 
cells to oxidative stress, protein misfolding, and resultant apoptosis and degeneration.  
Understanding which cells are most susceptible could provide valuable evidence pointing 




MATERIALS AND METHODS 
Meta-Analysis Procedure 
The statistical variation across experimental studies has made drawing specific 
conclusions on the ALS HSP response difficult.  Therefore, to provide more statistically 
conclusive clarity with a larger sample size of data, we performed a meta-data analysis 
aggregated from 11 peer-reviewed experimental journal articles examining HSPs in 
SOD1 G93A ALS mice.  Meta-analyses and meta-data analyses are commonly used in 
clinical practice to reconcile potential differences in a field or treatment strategy.  The 
same general methods can also be applied to experimental data.  The general meta-
analysis method involved (1) selecting and recapturing published data for SOD1-G93A 
mouse analysis on HSPs and oxidative stress interactions; (2) normalizing recaptured 
data to see conditional trends; (3) plotting and analyzing normalized data to create visual 
trend lines and statistical comparisons for each treatment condition.  
Article Selection 
Keyword Searches 
 Articles were found through a series of keyword searches in the SOD1 G93A 
experimental database owned and maintained by the Laboratory for Pathology Dynamics 
(Dr. Cassie Mitchell) at the Georgia Institute of Technology. This publicly available 
database has peer-reviewed publications from ALS transgenic mouse models, namely the 
SOD1 G93A ALS mouse model [29].   To search for articles, a script was made in the 
FileMaker Pro application. This script was designed to isolate articles that contained any 
mention of HSPs and/or oxidative stress in the following locations of each article in the 
database: abstract; figure captions; treatment description; and data series and response 
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descriptions. Through searches in these article sections using the keywords “HSP” or 
“heat-shock,” and “oxidative stress,” 66 potential articles were found. The suitability of 
these initial 66 articles was then determined based on specific study inclusion criteria. 
Inclusion and Exclusion Criteria 
Articles were excluded if they met ANY of the following criteria: contained data 
that did not directly or indirectly measure HSP concentration; contained data that 
involved treatments on the mouse model; exhibited purely in vitro data.  
For studies to be included in further analysis, they needed to contain data that 
measured concentration of any HSP, including: HSP70; HSP40; HSP60; HSP90; HSPb8; 
HSP25; HSP27; HSP105; and HSPh1, at one or more time points in spine or muscle 
tissue samples from wild-type or B6SJL or C57BL/6 SOD1-G93A congenic mice. 
Through these criteria, 11 of the 66 articles found via keyword search were determined to 
have suitable data for analyzing HSP levels in ALS, and the other 55 articles were 
excluded. Figure 1 illustrates the breakdown of articles found via keyword searches as 
well as the general filtering process. Table 1 shows the total number of data points and 
articles used in each analysis.  
 
Figure 1. Distribution of Articles Found by Keyword Search. A) Of the 66 total articles, there were 29 
articles with quantitative data, a necessity to include in this meta-analysis; 14 articles contained data on 
HSP levels; 19 articles utilized the desired mice. A total of 11 articles met all three of these inclusion 
criteria. B) HSP70 contained the most individual articles (19) of any individual HSP. 5 of these articles 
contained HSP level data and used the desired mouse type in the study. These 5 articles are included in the 





In order to recapture the data from the desired studies, articles were either 
downloaded using PubMed Central or from e-journal subscriptions available from the 
libraries of Georgia Institute of Technology and Emory University. Data was recaptured 
from the following article locations [15], referred to as entities: article title; abstract; figure 
captions; and data series and response values. Data was transferred from the full-text pdf 
article to the Laboratory for Pathology Dynamics SOD1 G93A ALS mouse database. To 
insure accuracy (>99%), every data point was reviewed by an independent quality control 
team[29].  
 
Data Aggregation and Normalization 
The data used from the selected articles all presented HSP quantified levels. 
However, the procedures that each study used to measure HSP data varied. To account 
for the variation of HSP level measurement methods between articles, HSP level data 
were normalized by calculating the ratios of transgenic SOD1-G93A to Wildtype (WT) 
HSP levels. Data from each study were normalized to their respective WT data, and ratios 
obtained from each article were weighted equally when calculating averages.  
Mouse Models and Tissue Collection 
 All articles used in this meta-analysis received B6SJL or C57BL/6 SOD1-G93A 
or WT mice from Jackson Laboratories (Bar Harbor, ME) [6-7,10,12-14,16,21,23-25]. 
Researchers for each article isolated either the spine or muscles of the mice and recorded 
HSP levels of tissue samples from these sources. In all studies analyzing HSP levels in 
muscles, a combination of soleus, transverse abdominal (TA) muscle, and/or extensor 
digitorum longus (EDL) muscle was used [6,10,13-14,16,23]. For the purpose of this study, 




  A Mann-Whitney U-test was implemented in Matlab (Mathworks, Inc.) to test for 
significance of HSP levels between spine and muscle at each time stage as well as 
between time stages within spine or muscle data sets. Unless otherwise stated, 









Category Articles Data points  References 
________________________________________________________________________ 
All HSP   11    57   [7,8,15,18-20,27,36,39-41]   
Spine    8    41   [7,8,18,19,27,39-41] 
Muscle   7    16   [7,15,19,20,27,36,39] 
Hsp70    8    25   [15,18-20,27,39-41] 
Table 1. Article and Data Point Breakdown 
8 
 
CHAPTER 3  
RESULTS 
 
Heat-Shock Protein 70 Levels in Spine and Muscles 
HSP70 was the most frequently analyzed heat shock protein in these studies. 
HSP70 levels were analyzed in 8 of the 11 articles and comprised 30 of the 57 total data 
points. SOD1-G93A/WT ratios of concentration data for HSP70 were divided into early 
and late stages of disease progression. To create the two individual data-sets, data points 
were sorted into the “early” stage if they were recorded between 30 and 99 days as (30 
days being the earliest time point in any article). Data points recorded after 99 days were 
sorted into the “late” stage of disease progression.  Note that, by 100 days, untreated 
SOD1 G93A ALS mice are considered to have measurable functional symptom onset, 
which is why 100 days was used as the threshold for binning the two groups.  These two 
sets of data were further divided into “muscle” and “spine” data sets based on the tissue 
samples analyzed in each report. All data points in each of the four groups were averaged 
and plotted (Figure 2). Differences in HSP70 levels between spine and muscle groups at 
each time stage were tested for statistical significance (eg. Early stage spine data was 
compared to early stage muscle data). Results revealed by Mann-Whitney U-Test that, at 
an alpha value of .10, early-stage spinal HSP70 levels (n=11) were significantly higher 
(p=.08) than early-stage muscle levels (n=5). While the late-stage spinal HSP70 levels 
(n=9) are higher than HSP70 muscle levels (n=5), with values of 1.34 for spine and 0.99 
for muscle, no significance was observed between these data sets. The significance of 
HSP70 levels was also assessed between each time stage within each tissue sample group 
(eg. Early stage muscle data was compared to late stage muscle data). However, no 
significance was observed between early and late stage HSP70 levels within spinal 
(early= 1.31, late=1.34) or muscle data (early=0.935, late=0.992). In order to assess the 
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contrasting HSP70 levels in the spine and muscle on a larger scale, the early and late 
stage data sets were combined. The average HSP70 levels in spinal tissue samples (n=20) 
were found to be significantly higher (p<.05) than the average HSP70 levels in muscle 
tissue samples (n=10). The results are in-line with what was stated in articles comparing 
HSP70 levels in the spine and muscles [40]. 
 
Figure 2. HSP70 Concentrations in Spine and Muscle. HSP70 data was divided into Spine and Muscle 
categories based on the reported tissue sample location in each article. This data was analyzed both as a 
total average and at different time bins to represent disease progression. Statistical significance was 
determined by a Mann-Whitney U-Test. *p<.05. **p<0.10. 
 
Overall Heat Shock Protein Trends in the Spine and Muscles 
For assessment of overall trends in HSP levels in the spine and muscles, data from 
all individual HSPs, including HSP70, were combined into a single, overarching group. 
This data was then divided into spine and muscle based on the tissue samples analyzed in 
each report. Analysis of this data via Mann-Whitney U-Test indicated that, at an alpha 
value of .10, heat-shock protein expression is significantly elevated (p=.0803) in the 




Figure 3. HSP Concentrations in Spine and Muscle. SOD1-G93A/WT Ratios from all HSPs was divided 
into Spine and Muscle categories based on the reported tissue sample location in each article. Statistical 
significance was determined by a Mann-Whitney U-Test. **p<0.10. 
 
Heat Shock Protein Trends in the Spine and Muscles at Different Time Bins 
HSP levels in each tissue sample location were divided into three separate time 
stages: 30-69 days (nspine= 9; nmuscle= 5); 70-110 days (nspine= 17; nmuscle = 6); and 111-150 
days (nspine= 15; nmuscle = 5). The time intervals were selected in such a way that each 
stage would cover about the same amount of days and would roughly align with known 
disease stages from the high copy SOD1 G93A transgenic ALS mouse literature (30-69 
days is pre-onset), (70-110 days is onset), and (111-150 days is late or end stage). Results 
indicated spinal tissue samples have mostly up-regulated HSP levels (30-69 days= 0.99; 
70-110 days=1.21; 111-150 days=1.21), higher than in muscle samples (30-69 days= 1.0; 
70-110 days= 0.852; 111-150 days= 1.02) at each time interval, but no quantitative 




Figure 4. HSP Concentrations in Spine and Muscle at Different Time Stages. HSP data was divided 
into Spine and Muscle categories based on the reported tissue sample location in each article. This data was 
analyzed both as a total average and at different time bins to represent disease progression. Statistical 
significance was determined by a Mann-Whitney U-Test. *p<.05. **p<0.10. 
 
HSP Levels in Transgenic SOD1-G93A Mice Compared to WT Mice 
To determine the overall effects of ALS on HSP concentration, data from SOD1-
G93A mice was compared to WT data. As all data was aggregated by finding the ratio of 
SOD1-G93A to WT values, the WT data for these analysis purposes was set to 1. To 
ensure equal weight of the two data sets, the sample size of the WT data was set equal to 
the sample size of the SOD1-G93A data (n=54). This data was first analyzed as an 
average value of all data points (Figure 5). SOD1-G93A data (average= 1.10) was found 
to be upregulated compared to WT (average= 1). However, Mann-Whitney U-Test 




Figure 5. HSP Concentrations in SOD1-G93A Mice. All HSP data was combined into a single SOD1-
G93A group. The SOD1-G93A/WT ratios were compared to the WT/WT ratio of 1. Statistical significance 
was determined by a Mann-Whitney U-Test. *p<.05. **p<0.10. 
  
HSP Levels in G93A Mice Compared to WT at Different Time Bins 
SOD1-G93A data was separated into individual time bins of 30-59 (n=12), 60-89 
(n=13), 90-119 (n=16), and 120-150 days (n=16) (Figure 6). Statistical significance 
between SOD1-G93A and WT at each time bin was then determined. In all time bins, 
SOD1-G93A/WT HSP level ratios were found to be higher than the WT value of 1, but 
no quantitative statistical significance was observed. The change in SOD1-G93A HSP 
levels at each time bin was also analyzed (eg. 30-59 days SOD1-G93A data was 
compared to 60-89 days SOD1-G93A data). Average HSP levels increased from 30-59 
days (average= 1.01) to 60-89 days (average= 1.08) and from 60-89 days to 90-119 days 
(average= 1.16), but decreased from 90-119 days to 120-150 days (average=1.13). In all 




Figure 6. HSP70 Concentrations in Spine and Muscle. All HSP data was combined into a single SOD1-
G93A group. The SOD1-G93A/WT ratios were compared to the WT/WT ratio of 1. This data was analyzed 
at different time bins to represent disease progression. Statistical significance was determined by a Mann-














Heat Shock Response in the Spine and Muscles 
 The results of the meta-analysis revealed that there are discernable qualitative 
increases in HSPs in both the spine and muscle of SOD1 G93A ALS mouse, but the 
increases in HSPs in the spine are more exaggerated, particularly in pre-onset and onset 
stages.  Given that the SOD1 G93A HSPs increases compared to wild type mice range 
from 1-20%, a much larger sample size is needed to overcome the large experimental 
error (variance) to illustrate quantitative statistically significant upregulation of HSPs.   
Nonetheless, the consistent qualitative trends do illustrate that an HSP upregulation is 
present, although insufficient, to combat the oxidative stress that co-exists in the ALS 
pathology.   
Given the significantly larger concentration of HSPs in the spine compared to the 
muscles, and the fact that motoneurons have been observed to have a higher activation 
threshold for the heat shock response [6], it was determined that the heat shock response in 
the muscles is more susceptible to insufficient production of HSPs to compensate for the 
negative effects of oxidative stress. In the early stages of the disease, HSP70, which has 
been determined in the past to be a critical HSP in the defense against protein misfolding 
caused by oxidative stress [38], was found to be significantly more upregulated in the 
spine compared to the muscles. This result indicates that there is a discrepancy of HSP 
levels in the spine and muscle that exists well before functional ALS symptom onset.   
Presence of Heat Shock Proteins as Evidence of Retrograde Pathology in ALS 
 A common characteristic and hypothesized factor of cell death in ALS is protein 
misfolding due to oxidative stress [40]. Past reports have shown that HSPs, due to the 
active role they play in assisting with protein folding, are upregulated in SOD1 G93A 
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cells in an attempt to combat the negative effects of oxidative stress [6,40]. The results of 
this study support the findings of these previous reports as HSP levels were found to 
qualitatively increase, albeit without statistical significance, as the disease progresses and 
the effects of oxidative stress worsen. However, HSP levels in the muscles were 
significantly lower than in the spine, thus leaving muscle cells comparatively more 
vulnerable to protein misfolding than spinal cord motoneurons. Given that the 
discrepancy of HSP70 levels, in particular, begins early in disease progression, and the 
fact that protein misfolding leads to cell death, it appears that muscle cells are more 
vulnerable to early degeneration than spinal motoneurons. These results are supportive of 
the retrograde mechanism proposed by the “dying-back” theory, which hypothesizes that 
ALS begins in the muscle cells or NMJ and that degeneration of spinal cord motoneurons 
may occur as a consequence of the loss of muscle cells and early degeneration of NMJ 
[9,40]. The significance of this retrograde mechanism is that it proposes a specific 
pathological trend for disease progression. Therefore, it is possible that in at least a 
portion of ALS cases, cell degradation begins in the muscle cells of the limbs, rather than 
in the spinal motoneurons; in such cases, muscle cells become a key therapeutic target for 
early ALS intervention.  In fact, results suggesting a greater susceptibly of muscles cells 
to insufficient HSP upregulation could support an initiating mechanism for limb onset 
ALS, one of the two most common forms of ALS, where muscle weakness begins in the 
extremities [37].   
Even though the results of this meta-analysis qualitatively illustrate that muscles 
are more vulnerable from the standpoint of insufficient HSP upregulation, it does not 
mean that HSPs are the root cause of all ALS cases, as ALS is thought to be multi-
factorial, with up to 10 different ontological pathophysiology categories contributing to 
the disease [25].  Nonetheless, these findings do suggest that it is plausible that at least in 
some cases, retrograde degeneration from the neuromuscular junction could be an 
initiating mechanism of ALS spread. 
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Finally, it has also been experimentally determined that the fast-acting 
motoneuron fibers die first in ALS. Fast-acting fibers (synapsing on Type IIb/x muscle 
fibers) work cooperatively with fast-resistant (also called intermediate) fibers and slow 
muscle fibers as part of a motor unit [26]. Among the fibers in this motor unit, fast fibers 
are known to have a deficiency of mitochondrial superoxide dismutase, leading to an 
increase in oxidative stress in fast-acting muscles [10]. Previous studies have exhibited that 
the increase in oxidative stress results in fast fibers having a higher vulnerability to 
synaptic denervation than intermediate or slow fibers, and loss of Type IIb/x muscle 
fibers during the early stages of disease progression [3,1,13,32,35]. These findings provide 
further support for the dying back theory as they present evidence of synapses, including 
NMJs, degrading before the loss of the entire spinal motoneuron cell body occurs, thus 
suggesting a potential retrograde mechanism for ALS pathology [12].  
Heat Shock Proteins as a Potential Treatment 
Previous studies have shown a positive correlation between survival time in mice 
and HSP concentration [14,19,20]. As the results of this study have shown, the Heat Shock 
response is weaker in the muscles than in the spine from the early stages of the disease, 
making muscles more susceptible to protein misfolding and consequently cell death. 
Coupling this finding with the theory that early degradation of muscle cells can result in 
the degeneration of spinal motoneurons, there exists promising optimism that early 
treatment of muscle cells with HSPs could delay or even prevent early muscle cell 
degeneration.  The fact the native HSP upregulation is enhanced earlier in the ALS 
pathology suggests that, in both muscles and spinal motoneurons, that as the disease 
progresses, compensatory upregulation begins to fail.  Thus, artificial upregulation of 
HSPs via HSP pharmaceutical treatment could possibly provide the needed compensation 
to combat ALS-associated oxidative stress.  One possible treatment vehicle could be the 
injection of HSPs near the neuromuscular junction, which would also enable the 
retrograde axonal transport of injected HSPs to the spinal motoneurons, providing dual 
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protection for both muscle and spinal motoneuron.  Preventing early muscle cell 
degeneration would, in theory, prolong the life of both muscle cells and spinal 
motoneurons, which in turn could potentially prolong survival of ALS patients or 
minimally prolong post-onset quality of life. 
 
Future Heat Shock Protein Research 
 Future research regarding HSPs should be aimed at analyzing the concentrations 
of independent HSPs. This study performed specific individual analysis on HSP70 as 
well as aggregated HSP analysis. Studies on the progression and concentrations of 
independent HSPs would lead to a larger understanding of which specific HSPs, in 
particular, are downregulated in the spine.  For example, this study found that 
upregulated individuated HSP70 levels in the spine are not as apparent when multiple 
HSP types are aggregated and collectively assessed. The downregulation of other 
specific, individual HSPs could be indicative of a wider-spread inefficiency in the Heat-
Shock Response in the spine, in addition to what has been seen in the muscles. Therefore, 
future mapping of temporal individuated HSP levels across different cell types and 
locations could lead to a better understanding of which HSPs should be artificially 
upregulated as well as their optimal therapeutic target site. 
 
Homeostatic Instability in ALS 
The early pathophysiology of ALS, in its early stages, attempts to compensate for 
increased oxidants levels by increasing HSPs.  However, this response is overall 
inadequate, and antioxidant levels continue to rise. Regulatory or homeostatic instability 
can be seen in multiple pathways in ALS [17,28].  However, the compensation seen in 
HSPs [17] reveals that they are one of the earliest compensation mechanisms in ALS. As 
such, they could be an effective treatment target for early to mid-stage ALS. However, in 
reality, HSPs will likely have to be used in combination with other treatment targets to 
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combat the multi-faceted nature of ALS from the sub-cellular through system level. The 
use of combination therapies in cancer has been quite effective [21,22,23,24].  A similar 
polytherapy approach tailored to the disease progression stages of ALS and its multiple 
failed regulatory pathways may also be required to obtain clinically significant 







Days Spine Muscle Publication Hsp 
30   0.847826 Gifondorwa 1 70 
40 1   Yamashita 27 
40 1   Yamashita 70 
40 1   Yamashita 105 
50 0.727273   Wei 90 
50 0.9375   Wei 40 
50 1.046154 1 Wei 70 
50 1.148148 0.833333 Wei 60 
56 1.1875 1.4 Crippa 234 B8 
60 0.911458 0.785714 Kalmar 339 70 
70 1.5   Mimoto 70 
70 2.5   Mimoto 70 
70   0.87108 Sharp 27 
70   0.486885 Sharp 27 
72 0.7   Yamashita 27 
72 0.75   Yamashita 105 
72 0.8   Yamashita 70 
75   1.243243 Gifondorwa 1 70 
75 1   Kabashi 40 
75 1.615   Kabashi 70 
80 0.9   Vleminckx 70 
95 0.6875   Wei 40 
95 0.819672   Wei 90 
95 0.871429 0.8 Wei 70 
95 0.884615 0.75 Wei 60 
98 1.65   Mimoto 70 
98 1.666667   Mimoto 70 
100 0.859375 0.857143 Kalmar 339 70 
110 0.57   D'Arrigo h1 
110 2.81   D'Arrigo b1 
112 1.722222   Crippa 234 B8 
117 0.4   Yamashita 105 
117 1.3   Yamashita 70 
117 1.9   Yamashita 27 
120   0.675676 Kalmar 378 70 
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120   1.014493 Kalmar 378 70 
120 1.5   Vleminckx 70 
126 1.214286   Mimoto 70 
126 2.35   Mimoto 70 
130 0.927083 0.414286 Kalmar 339 70 
130 0.714286 1 Wei 60 
130 0.9   Wei 40 
130 0.909091 2 Wei 70 
130 1.5   Wei 90 
135 0.3   Yamashita 105 
135 1.6   Yamashita 70 
150 0.95   Vleminckx 70 
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